MedTrace Logo

Proton Pump Inhibitor (PPI) Therapy for Newly Diagnosed Esophagitis

NCT00586963 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 65

Last updated 2010-08-23

No results posted yet for this study

Summary

This study is being done to for two reasons:

* To learn about the effects (good and bad) esomeprazole (an FDA approved drug for reflux esophagitis) has on your esophagus when taken correctly.
* To learn about the quality of life changes (good and bad) you may experience with this medication.

Conditions

  • Erosive Esophagitis
  • Reflux Esophagitis
  • GERD

Sponsors & Collaborators

Principal Investigators

  • Yvonne Romero, MD. · Mayo Clinic

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2008-10-31
Completion
2008-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00586963 on ClinicalTrials.gov